



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Rastelli, et al

EXAMINER: Rawlings Stephen L.

SERIAL NUMBER: 10/016,253

ART UNIT: 1642

FILING: DATE: December 10, 2001

FOR: METHOD OF DETECTING AND TREATING TUBEROUS SCLEROSIS  
COMPLEX ASSOCIATED DISORDERS

**Mail Stop IDS**

Commissioner of Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page) in duplicate;
3. Copies of Cited references C8-C9 and;
4. Return Postcard

No fee is believed to be due at this time. However, the Commissioner is authorized to charge any additional fees that may be due to Deposit Account No.502648, Reference No. Cura 342 (21402-042). A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 203/974-6303, New Haven, Connecticut.

Respectfully submitted,

Date: April 26, 2004

George Yahwak, Reg. No. 26,824  
c/o CuraGen Corporation  
555 Long Wharf Drive  
New Haven, CT 06511  
Tel: (203) 974-6303  
Fax: (203) 401-3351



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Rastelli, et al.

EXAMINER: Rawlings Stephen L.

SERIAL NUMBER: 10/016,253

ART UNIT: 1642

FILING DATE: December 10, 2001

FOR: METHOD OF DETECTING AND TREATING TUBEROUS SCLEROSIS  
COMPLEX ASSOCIATED DISORDERS

**Mail Stop IDS**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents attached modified Form PTO-1449.

This Supplemental Information Disclosure Statement is being filed with in three months of the mailing date of the International Report of PCT/ US01/47839 . Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By Submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, or that more relevant information

does not exist; and (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The order of presentation of the references should not be constructed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, as a result of this submission to Deposit Account No. 502648, Reference No. 21402-042(Cura 342).

Respectfully submitted,



Date: April 26, 2004

---

George Yahwak, Reg. No. 26,824  
c/o CuraGen Corporation  
555 Long Wharf Drive  
New Haven, CT 06511  
Tel: (203) 974-6303  
Fax: (203) 401-3351

Express Mail No. EI#####US  
Date of Deposit: \_\_\_\_\_



Page 1 of 1

Please type a plus sign (+) in this box ☐

PTO/SB (12-97)  
Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	10/016,253
	<b>Filing Date</b>	12/10/01
	<b>First Named Inventor</b>	Rastelli, et al.
	<b>Group Art Unit</b>	1642
	<b>Examiner Name</b>	Rawlings Stephen L.
	<b>Attorney Docket Number</b>	21402-042 Cura 342

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1						

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1				

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C8	Bandari, P. S., J. Qian, et al. (2003). "Hematopoietic growth factor inducible neurokinin-1 type: a transmembrane protein that is similar to neurokinin 1 interacts with substance P." Regul Pept 111(1-3): 169-78.
	C9	Weternan, M. A., N. Ajubi, et al. (1995). "nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts." Int J Cancer 60(1): 73-81.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRADOCS: 1177824.1 (p8tc01!.doc)